We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Urges FDA to Flag Common Misconceptions About Biosimilars
Novartis Urges FDA to Flag Common Misconceptions About Biosimilars
Piggybacking on a petition from Pfizer, Novartis called on the FDA to debunk common myths about biosimilars and better educate consumers about their safety and efficacy.